LongeVC

About The Fund

LongeVC is an international venture capital firm dedicated to investing in groundbreaking advancements within the biotech sector, particularly focusing on the creation of a future where longevity is central. They predominantly support early-stage companies, deploying capital to visionary founders whose work promises to revolutionize healthcare and wellness. With a firm belief in the power of biotech to transform our health and extend our lifespans, LongeVC aims to usher in an era of personalized and preventive medicine that can comprehensively address the complex process of aging. The fund's focus is on pre-clinical and clinical stage drug development companies that delve into the molecular and cellular underpinnings of aging, as well as early-stage entities developing innovative solutions for personalized medicine, advanced diagnostics, foundational platform technologies, and integrated healthcare systems that expedite drug discovery and testing. Through their investment strategy, LongeVC allocates funds typically ranging from $100,000 to $5,000,000, with a 'sweet spot' average of around $1,500,000. These financial commitments primarily target start-ups at the Seed and Series A stages, nurturing an ecosystem that connects these companies with a global network of thought leaders and experts in the biotech and longevity space. The ultimate mission of LongeVC is ambitious: to back the science and the entrepreneurs that will not only change lives with innovative treatments and diagnostics but also curate an ageless future that redefines our approach to health and the science of aging.